

EquiRab™

Every horse. Every year.

with Havlogen®*

Rabies protection designed specifically for the horse.



Proven Protection & 14 Month DOI

Immunogenicity and Duration of Immunity (DOI) Study:

Vaccinates: 26 seronegative, mixed sex, 4 month-old (average) horses;
Received **one dose (1.0 mL)** of EquiRab Vaccine IM
Controls: 11 similar horses served as non-vaccinated controls

At 14 months post-vaccination, 16 horses were selected for rabies challenge according to 9 CFR 113.209 (b) (4) requirements:

5 vaccinates with the **lowest** RFFIT¹ titer at the 270th day bleeding
6 vaccinates² with the **lowest** RFFIT titer at the 365th day bleeding
5 unvaccinated RFFIT titer-negative horses

Post-challenge horses were observed daily for a minimum of 90 days for clinical signs consistent with rabies disease: excessive salivation or urination, loss of appetite, not drinking, depression, signs of paralysis, becoming vicious, coma or sudden death. Brain tissues of each test animal that died or was euthanized was examined for rabies virus by direct fluorescent antibody (DFA) test at CDC.

9 CFR 113.209 (b) (4) requirements for vaccine licensure, indicate study results must meet the following:

- All vaccinates that were challenged must survive the challenge.
- At least 80% of the control animals must succumb to rabies.

EquiRab's 14 month DOI study demonstrated the following results after one dose and supports the following label claim:

- 10 out of 10 vaccinates (100%) remained healthy and free of rabies disease or clinical signs during the 90 day observation period.²
- 4 out of 5 controls (80%) died within 22 days post-challenge, and the presence of rabies virus was confirmed by DFA testing.

For the vaccination of healthy horses, 4 months-of-age or older, as an aid in the prevention of disease caused by rabies virus up to 14 months following vaccination.

Rabies Is Now A "Core Vaccine"

While the incidence of rabies in horses is low, the disease is invariably fatal and has considerable public health significance. According to the new January 2008 AAEP Guidelines, it is recommended that rabies vaccine be a core vaccine for all horses.

intervet

RESEARCH • PERFORMANCE • INTEGRITY

Proven Safety: 97.7% Reaction-Free

Field Safety Trial Study Results:

Conducted by four veterinarians in three states; 992 healthy horses of various age, breed and sex, including 413 foals 4 months of age or younger.

- 992 horses received one dose of vaccine; 992 total doses were given
- All horses/foals were observed immediately and for one, two or three days post-vaccination for signs of adverse reactions
- Proven safe in field safety trials: 97.7% reaction-free

Unique Havlogen Adjuvant

- Intervet's proprietary adjuvant technology
- Maintains uniform suspension for consistency and potency – doesn't settle out
- Stimulates both cell-mediated (T-cells) and humoral (B-cells) immune responses
- Produces a booster effect, stimulating higher, longer-lasting protection through the slow release of antigens

Recommend EquiRab.

Contact your Intervet or distributor sales representative,
or call 1-800-441-8272, to order.



* Adjuvant—Intervet's Proprietary Technology

¹ Rapid Fluorescent Focus Inhibition Test

² One horse died on day 61 post-challenge without any neurological signs. DFA testing confirmed death was a non-rabies related cause.

www.equirab.com

EquiRab with Havlogen®*

DESCRIPTION: A liquid suspension of inactivated rabies virus propagated in a stable cell line. The efficacy of this vaccine has been demonstrated in controlled vaccination challenge tests and the safety in thorough field evaluations.

INDICATIONS: For vaccination of healthy horses, 4 months of age or older, as an aid in the prevention of disease due to rabies virus up to 14 months following vaccination.

DOSE: For primary immunization aseptically inject 1 mL intramuscularly. Annual revaccination is recommended. A booster dose can be administered at more frequent intervals based upon individual horse or farm disease risk assessment or any time epidemic conditions exist or are reported. Consult your veterinarian.

CAUTIONS: Store at 35° to 45°F (2° to 7°C). DO NOT FREEZE. SHAKE WELL BEFORE USING. Use entire contents when first opened. Do not vaccinate within 21 days before slaughter. Vaccinating animals whose immune response is compromised by stress, disease, etc. may not produce the desired results. Anaphylactic reactions may occur.

ANTIDOTE: Epinephrine.
Neomycin, polymyxin B and thimerosal added as preservatives.

SUPPLIED:

Code: 032396 10 x 1 mL (1 dose) sterile syringes per box, individually printed plastic bag with needle.
032585 10 mL (10 doses) vial.

FOR USE IN ANIMALS ONLY

P.O. Box 318
29160 Intervet Lane
Millsboro, Delaware 19966
www.intervetusa.com
800.441.8272

EquiRab is a trademark of Intervet Inc. or an affiliate. © 2008 Intervet Inc.
All rights reserved. 31948 EQ-BIO-1020-FS



RESEARCH • PERFORMANCE • INTEGRITY